Analysis of PRAME immunocytochemistry in 109 acral malignant melanoma in situ.

Autor:	Miao QJ; Department of Pathology, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Dermatology, Nanjing, Jiangsu, China., Zang J; Department of Pathology, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Dermatology, Nanjing, Jiangsu, China., Shao XB; Department of Pathology, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Dermatology, Nanjing, Jiangsu, China., Sun JF; Department of Pathology, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Dermatology, Nanjing, Jiangsu, China., Chen YP; Department of Pathology, Fujian Medical University cancer Hospital, Fuzhou, Fujian, China ch76ch@163.com kelf2006@126.com., Chen H; Department of Pathology, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Dermatology, Nanjing, Jiangsu, China ch76ch@163.com kelf2006@126.com.
Jazyk:	angličtina
Zdroj:	Journal of clinical pathology [J Clin Pathol] 2024 May 17; Vol. 77 (6), pp. 417-420. Date of Electronic Publication: 2024 May 17.
DOI:	10.1136/jcp-2022-208697
Abstrakt:	Aims: Preferentially expressed antigen in melanoma (PRAME) recently is a reliable immunohistochemistry (IHC) marker for distinguishing melanoma from other lesions. However, there are few articles focused on PRAME use in acral malignant melanoma, the most common type in Asians. This study investigated PRAME IHC expression in a large series of acral malignant melanoma in situ to add to the body of clinical knowledge. Methods: PRAME IHC was performed in unequivocal cases of primary acral lentiginous melanoma in situ (ALMIS), subungual melanoma in situ (SMIS) and acral recurrent nevi as the control. PRAME tumour cell percentage positivity and intensity were expressed as categorised in a cumulative score by adding the quartile of positive tumour cells to intensity labelling. The final IHC expression was interpreted as negative (0-1), weak (2-3), moderate (4-5) or strong (6-7). Results: In 91 ALMIS patients, 32 cases (35.16%) were strong, 37 (40.66%) were moderate and 22 (24.18%) were weak. In 18 SMIS patients, strong positivity of PRAME was observed in 4 (22.22%) cases, moderate in 10 (55.56%) and weak in the remaining 4 (22.22%). No melanoma sample was negative for PRAME. By comparison, only 2 of the 40 acral recurrent nevi cases were positive. Conclusions: Our study supports the ancillary value of PRAME for diagnosing ALMIS and SMIS with high sensitivity and specificity. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu